(Q41112387)

English

An in vivo safety and efficacy demonstration of a topical liposomal nitric oxide donor treatment for Staphylococcus aureus biofilm-associated rhinosinusitis

scientific article published on 24 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

An in vivo safety and efficacy demonstration of a topical liposomal nitric oxide donor treatment for Staphylococcus aureus biofilm-associated rhinosinusitis (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

0 references

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Benjamin Thierry

object named as

Benjamin Thierry

2

0 references

Peter-John Wormald

13

object named as

Peter-John Wormald

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Camille Jardeleza

1

object named as

Camille Jardeleza

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

4

object named as

Sukanya Rajiv

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Amanda J Drilling

5

object named as

Amanda Drilling

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sathish Paramasivan

7

object named as

Sathish Paramasivan

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

3

object named as

Shasha Rao

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Clive A Prestidge

12

object named as

Clive A Prestidge

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Dijana Miljkovic

6

object named as

Dijana Miljkovic

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

author name string

Craig James

8

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Dong Dong

9

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

publication date

24 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Translational Research

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

166

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

683-692

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Methylglyoxal-infused honey mimics the anti-Staphylococcus aureus biofilm activity of manuka honey: potential implication in chronic rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Methylglyoxal-augmented manuka honey as a topical anti-Staphylococcus aureus biofilm agent: safety and efficacy in an in vivo model

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Methods for removing bacterial biofilms: in vitro study using clinical chronic rhinosinusitis specimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Topical Drug Delivery for Chronic Rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

In vivo effects of citric acid/zwitterionic surfactant cleansing solution on rabbit sinus mucosa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

High nitric oxide production in human paranasal sinuses

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Nasal nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Nitric oxide and the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Effects of nitric oxide on blood flow and mucociliary activity in the human nose

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Nitric Oxide (NO) Production in the Upper Airways is Decreased in Chronic Sinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Nasal nitric oxide in objective evaluation of chronic rhinosinusitis therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Liposome-encapsulated ISMN: a novel nitric oxide-based therapeutic agent against Staphylococcus aureus biofilms

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

A sheep model to investigate the role of fungal biofilms in sinusitis: fungal and bacterial synergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

A sheep model for the study of biofilms in rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

The efficacy of topical antibiofilm agents in a sheep model of rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Biofilm formation by Staphylococcus aureus and Pseudomonas aeruginosa is associated with an unfavorable evolution after surgery for chronic sinusitis and nasal polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Different biofilms, different disease? A clinical outcomes study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Staphylococcus aureus biofilms: Nemesis of endoscopic sinus surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

The effects of nitric oxide on Staphylococcus aureus biofilm growth and its implications in chronic rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Effect of oral nitrates on pulse pressure and arterial elasticity in patients aged over 65 years with refractory isolated systolic hypertension: study protocol for a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Abrupt withdrawal of isosorbide-5-mononitrate in Durules (Imdur) after long term treatment in patients with stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

The role of biofilms in otolaryngologic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Bacterial biofilms: from the natural environment to infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Evolving concepts in biofilm infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Antibiotic resistance of bacteria in biofilms

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

A randomized trial of mupirocin sinonasal rinses versus saline in surgically recalcitrant staphylococcal chronic rhinosinusitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Microbiological outcomes following mupirocin nasal washes for symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis following endoscopic sinus surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Inhibition of staphylococcal biofilm formation by nitrite

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

"Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.06.009

7 January 2021

Identifiers

10.1016/J.TRSL.2015.06.009

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41112387&oldid=2094038497"